April 14 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB PROVIDES UPDATE ON PHASE 3 ODYSSEY-HCM TRIAL
BRISTOL-MYERS SQUIBB CO - BMS PHASE 3 ODYSSEY-HCM TRIAL DID NOT MEET PRIMARY ENDPOINTS
BRISTOL-MYERS SQUIBB CO - NO NEW SAFETY SIGNALS OBSERVED IN ODYSSEY-HCM TRIAL
BRISTOL-MYERS SQUIBB CO - ODYSSEY-HCM TRIAL ENROLLED 580 PATIENTS WORLDWIDE
Source text: ID:nBw6MwlxHa
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.